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Alkaline phosphatase (Alk-Phos) is a powerful predictor of death in patients with end-stage kidney disease (ESKD) and oxidative
stress is a strong inducer of Alk-Phos in various tissues. We tested the hypothesis that oxidative stress, as estimated by a robust
marker of systemic oxidative stress like 𝛾-Glutamyl-Transpeptidase (GGT) levels, may interact with Alk-Phos in the high risk of
death in a cohort of 993 ESKD patients maintained on chronic dialysis. In fully adjusted analyses the HR for mortality associated
with Alk-Phos (50 IU/L increase) was progressively higher across GGT quintiles, being minimal in patients in the first quintile
(HR: 0.89, 95% CI: 0.77–1.03) and highest in the GGT fifth quintile (HR: 1.13, 95% CI: 1.03–1.2) (𝑃 for the effect modification =
0.02).These findings were fully confirmed in sensitivity analyses excluding patients with preexisting liver disease, excessive alcohol
intake, or altered liver disease biomarkers. GGT amplifies the risk of death associated with high Alk-Phos levels in ESKD patients.
This observation is compatible with the hypothesis that oxidative stress is a strong modifier of the adverse biological effects of high
Alk-Phos in this population.
1. Introduction
Tissue nonspecific alkaline phosphatase (Alk-Phos) is an
enzyme highly represented in the bone and in the liver
and the measurement of the activity of this enzyme is a
time-honored biomarker applied for the diagnosis and the
clinical monitoring of bone and liver diseases [1]. Alk-Phos
catalyzes the hydrolysis of pyrophosphate, the main calcifi-
cation inhibitor, and seminal studies in patients with end-
stage kidney disease (ESKD) documented that circulating
Alk-Phos activity is robustly related to the risk of death
[2–4]. In ESKD patients Alk-Phos mainly reflects increased
bone turnover [1], triggered and maintained by secondary
hyperparathyroidism and modulated by several other factors
among which oxidative stress [5] plays a relevant role.
Oxidative stress is notoriously pervasive in ESKD patients
[6, 7]. Among biomarkers of oxidative stress, 𝛾-Glutamyl-
Transpeptidase (GGT) is now regarded as one of the most
robust indicators of whole body oxidative stress [8, 9]. High
levels of GGT predict mortality in ESKD patients [10, 11]
and in the general population [12] being associated with
a high risk for coronary heart disease [12, 13] and heart
failure [14]. Of note, oxidative stress is a powerful inducer
of Alk-Phos in vascular and bone cells [15] and is key to
vascular calcification [16]. Even though the predictive power
ofAlk-Phos for adverse clinical outcomes has been previously
confirmed in ESKD [17–23], the possible interaction between
Alk-Phos and biomarkers of oxidative stress like GGT has
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Table 1: Main demographic, somatometric and clinical characteristics in the whole study population and in patients as divided according to
alkaline phosphatase quartiles.
Whole group
(𝑛 = 993)
Alk-Phos <median
value (𝑛 = 497)
Alk-Phos >median
value (𝑛 = 496)
𝑃 for linear
trend
Age (years) 65 ± 14 65 ± 14 65 ± 13 0.93
BMI (kg/m2) 25 ± 5 25 ± 5 25 ± 5 0.74
Male sex 𝑛. (%) 624 (63) 343 (69) 281 (57) <0.001
Current smokers 𝑛. (%) 149 (15) 78 (16) 71 (14) 0.54
Past smokers 𝑛. (%) 370 (37) 202 (41) 168 (34) 0.03
Diabetics 𝑛. (%) 272 (28) 127 (26) 145 (30) 0.14
On antihypertensive treatment 𝑛. (%) 634 (64) 320 (64) 314 (63) 0.72
Dialysis vintage (months) 45 (21–85) 38 (19–76) 52 (26–96) <0.001
With cardiovascular comorbidities∗ 𝑛. (%) 533 (54) 257 (52) 276 (56) 0.21
Systolic blood pressure (mmHg) 135 ± 22 135 ± 22 135 ± 23 0.99
Diastolic blood pressure (mmHg) 74 ± 12 74 ± 12 73 ± 11 0.09
Pulse pressure (mmHg) 74 ± 11 73 ± 10 74 ± 11 0.13
Cholesterol (mg/dL) 156 ± 40 155 ± 39 156 ± 41 0.61
Haemoglobin (g/dL) 11.3 ± 1.5 11.3 ± 1.4 11.3 ± 1.5 0.96
Albumin (g/dL) 3.9 ± 0.5 3.9 ± 0.5 3.9 ± 0.5 0.87
CRP (mg/L) 5.0 (3.0–13.0) 4.1 (2.9–12.0) 5.7 (3.0–14.0) 0.02
Calcium (mg/dL) 9.1 ± 0.9 9.2 ± 0.9 9.0 ± 0.9 0.001
Phosphate (mg/dL) 5.0 ± 1.6 5.2 ± 1.6 4.9 ± 1.6 0.001
∗Cardiovascular comorbidities: the presence, at baseline, of at least one of these comorbidities: angina, arrhythmia, myocardial infarction, coronary surgery,
angioplasty, other heart surgeries, claudicatio intermittens, amputations, peripheral surgery, stroke, TIA, and preexisting chronic heart failure.
Data are expressed as mean ± SD or median and interquartile range or as percent frequency, as appropriate.
not been investigated so far. As oxidative stress and mineral
metabolism are intimately related phenomena in ESKD [5],
we investigated if GGTmodifies the association betweenAlk-
Phos and all-cause and cardiac mortality in a sizable cohort
of patients with ESKD maintained on chronic dialysis.
2. Methods
The study protocol was approved by the ethical committee of
our institution. All participants gave their informed consent
before enrolment.
2.1. Study Population. The study population is part of a
cohort of 1189 dialysis patients enrolled in the PROGREDIRE
(Prospective Registry of The Working Group of Epidemiol-
ogy of Dialysis Region Calabria), a cohort study involving
35 dialysis units in two regions in Southern Italy (Calabria
and Sicily). We included in this analysis 993 patients in
which bothAlk-Phos andGGTmeasurementswere available.
Patients where Alk-Phos and GGT were not available (𝑛 =
196, 16%) did not differ from those included in the study
for any of the main demographic, clinical, and biochemical
characteristics listed in Table 1.
Patients had been on regular dialysis [haemodialysis
(HD) or peritoneal dialysis (PD)] for a median time of
3.0 years (interquartile range: 1.8–4.4 years). HD patients
(𝑛 = 932) were being treated with standard bicarbonate
dialysis with noncellulosic membrane filters of various types.
PD patients (𝑛 = 61) were either on 4 standard exchanges per
day or on continuous cycling peritoneal dialysis. Six hundred
and thirty-four patients were treated with various antihy-
pertensive drugs (271 on monotherapy with ACE inhibitors,
calcium channel blockers, 𝛼- and 𝛽-blockers, vasodilators,
diuretics, or other drugs, 194 on double therapy, 92 on
triple therapy, and 77 patients on quadruple or quintuple
therapy with various combinations of these drugs). The
main demographic, somatometric, clinical, and biochemical
characteristics of the study population are detailed in Table 1.
2.2. Laboratory Measurements. Blood sampling was per-
formed at baseline after an overnight fast. For HD patients,
blood was always drawn during a mid-week day (brief
dialysis interval). Alk-Phos, GGT, cholesterol, albumin, cal-
cium, phosphate, C-Reactive Protein (CRP), haemoglobin,
Glutamic-Oxaloacetic Transaminase (GOT), and Glutamic-
Pyruvic Transaminase (GPT) measurements were made
using standard methods in the routine clinical laboratory.
In our laboratory, the normal range of Alk-Phos was 30 to
120UI/L and that of GGT was 0–45UI/L.
2.3. Study End Points. Mortality and fatal and nonfatal
cardiac events were themain study end points. Cardiac events
were classified as follows: myocardial infarction confirmed
by serial changes of ECG and cardiac biomarkers; ECG-
documented angina episodes; ECG-documented arrhythmia;
unexpected, sudden death highly suspected as of cardiac
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origin. De novo chronic heart failure (CHF) was defined as
CHF in a patient without CHF at baseline. To be classified
as having CHF patients had to show mild or more severe
dyspnoea during ordinary activities (NYHA class II or
higher) plus evidence of anatomical/functional LV disease
on echocardiography. Each cause of death was assessed
by 3 independent physicians. In doubtful cases, diagnosis
was attributed by consensus. During the review process,
involved physician used all available medical information,
including hospitalization forms and medical records. In
case of death occurring at home, family members and/or
general practitioners were interviewed to better understand
the circumstances which led to death.
2.4. Statistical Analysis. Data were expressed as mean ±
standard deviation (normally distributed data) or median
and interquartile range (nonnormally distributed data) or as
percent frequency (categorical data). Comparisons among
groups were made by one-way ANOVA, Kruskal-Wallis, or
Chi Square test, as appropriate. Regression analysis was
performed to investigate the relationship between Alk-Phos,
GGT, and markers of liver function and bone mineral
metabolism. Due to the nonnormal distribution of both
Alk-Phos and GGT both variables were log-transformed
before analysis. Survival analyses were performed by using
both univariate and multivariate Cox regression analyses,
including Alk-Phos, GGT, and their interaction term as well
as traditional [age, gender, current smoking, diabetes, choles-
terol, arterial pressure and antihypertensive treatment, and
cardiovascular comorbidities], inflammation and nutritional
status [CRP, BMI, and albumin], and ESKD-related risk
factors [dialysis vintage, haemoglobin]. ALT, AST, HbsAg,
HCV, alcohol consumption, and preexisting liver disease
were always included in the multivariate models. The hazard
ratios of alkaline phosphatase across GGT categories were
calculated by the standard linear combination method. The
best functional form of GGT (i.e., quintiles) was chosen
by analysing the Martingale residuals in Cox’s regression
analysis [24]. Multivariate models were built as previously
described. Statistical analysis was performed by using stan-
dard statistical packages (SPSS for Windows, Version 20,
Chicago, Illinois, USA; STATA for Windows, Version 13,
College Station, Texas, USA).
3. Results
The main baseline characteristics of the study population
are reported in Table 1. Both Alk-Phos and GGT distribu-
tions were right-skewed and the median value of the two
biomarkers was 89UI/L and 20UI/L, respectively (Figure 1).
Two hundred and seventy-one patients (27%) had Alk-
Phos exceeding the upper limit of the normal range of this
biomarker (120UI/L) and 83 (17%) had GGT greater than
45UI/L (the upper limit of the normal range). Sixty-three
percent of patients were males and mean age was 65 years.
Diabetics were 28%. Alk-Phos levels were higher in female
patients (median 97UI/L, IQR: 74–140UI/L) than in male
patients (median 85UI/L, IQR: 64–116UI/L). Patients with
higher levels of Alk-Phos had been on dialysis for longer
time and had higher CRP levels. Conversely, calcium and
phosphate levels showed an opposite trend (Table 1).
3.1. Correlates of Alkaline Phosphatase and 𝛾-Glutamyl-
Transpeptidase. Alk-Phos showed a direct, highly significant
association with GGT (𝑟 = 0.26, 𝑃 < 0.001) (Figure 1).
Furthermore, Alk-Phos was directly associated with GOT
(𝑟 = 0.13, 𝑃 < 0.001), GPT (𝑟 = 0.14, 𝑃 < 0.001), and
Parathyroid Hormone (PTH) (𝑟 = 0.38, 𝑃 < 0.001) and
correlated inversely with calcium (𝑟 = −0.13, 𝑃 < 0.001) and
phosphate (𝑟 = −0.16, 𝑃 < 0.001). The same variables, except
PTH, were associatedwithGGT [GGT versus GOT (𝑟 = 0.40,
𝑃 < 0.001); GGT versus GPT (𝑟 = 0.41, 𝑃 < 0.001); GGT
versus calcium (𝑟 = −0.08, 𝑃 = 0.01); GGT versus phosphate
(𝑟 = −0.14, 𝑃 < 0.001)].
3.2. Survival Analysis: All-Cause Death. During a median
follow-up of 3.0 years (interquartile range: 1.8–4.4 years), 405
patients died. In a basic model including Alk-Phos, GGT, and
their interaction term, GGT significantly amplified the risk
of death across progressively increasing Alk-Phos levels (𝑃
for the effect modification = 0.004) (Table 2, crude analysis).
These results were confirmed in fully adjusted analyses, where
the risk associated with 50UI/L increase of in Alk-Phos for
all-cause mortality was progressively higher from the first to
the fifth quintile (1st quintile: HR: 0.89, 95% CI: 0.77–1.03;
2nd quintile: HR: 0.95, 95% CI: 0.85–1.05; 3rd quintile: HR:
1.01, 95% CI: 0.94–1.08; 4th quintile HR: 1.07, 95% CI: 1.01–
1.14, 5th quintile HR: 1.13, 95% CI: 1.03–1.2) (𝑃 for the effect
modification = 0.02). (Table 2; Figure 2). Exclusion of heavy
drinkers (𝑛 = 23) and of patients affected by chronic liver
diseases (𝑛 = 68) only modestly reduced the HR of the Alk-
Phos-GGT interaction (HR: 1.06, 95% CI: 1.01–1.12).
4. Discussion
In this study, GGT, a systemic marker of oxidative stress,
emerged as a coherent amplifier of the death risk portended
by high Alk-Phos in ESKD patients on dialysis. This inter-
action was largely independent of liver disease and alcohol
intake and was confirmed in sensitivity analyses excluding
patients with preexisting liver disease or self-reported high
alcohol intake. Overall, these findings suggest that systemic
oxidative stress, as estimated by GGT, plays a relevant role in
predicting the risk for major clinical outcomes portended by
increased alkaline phosphatase.
Alk-Phos is an established predictor of death in ESKD
patients on haemodialysis. Several studies reported a linear
association between Alk-Phos levels and mortality in ESKD
[2–4, 17–23]. Additional studies focusing on predialysis CKD
patients showed that such a link is not peculiar to the end-
stage phase of CKD [25–27]. Furthermore, observational
studies in various communities documented that Alk-Phos is
a quite strong risk factor for death and cardiovascular events
in the general population [28].This enzyme is ubiquitous and
located at cell surface and it is directly involved in glutathione
catabolism, the main antioxidant system in humans [29, 30].
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Figure 1: Distribution of Alk-Phos and GGT and their correlation in the study population.
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Figure 2: Effect modification by 𝛾-Glutamyl-Transpeptidase on the relationship between alkaline phosphatase and all-cause mortality. The
HR in this graph represents the risk for all-cause death due to alkaline phosphatase across 𝛾-Glutamyl-Transpeptidase levels.
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Table 2: Crude and adjusted Cox regression analyses showing the effect modification of 𝛾-Glutamyl-Transpeptidase on alkaline phosphatase
for all-cause mortality. The criteria for building these models are detailed in the methods.
Variables (units of increase) Crude analysis Fully adjusted analysis
Alk-Phos (50UI/L) 0.80 (0.67–0.96), 𝑃 = 0.02 0.84 (0.69–1.02), 𝑃 = 0.08
GGT (quintiles) 0.96 (0.84–1.09), 𝑃 = 0.52 0.97 (0.85–1.12), 𝑃 = 0.72
Alk-Phos∗GGT (50UI/L∗quintiles) 1.08 (1.02–1.13), 𝑃 = 0.004 1.06 (1.01–1.12), 𝑃 = 0.02
Age (1 year) 1.05 (1.04–1.06), 𝑃 < 0.001
Gender (0 = female; 1 = male) 0.97 (0.77–1.21), 𝑃 = 0.77
Current smoking (0 = no; 1 = yes) 0.93 (0.67–1.29), 𝑃 = 0.66
Diabetes (0 = no; 1 = yes) 1.29 (1.03–1.62), 𝑃 = 0.03
Systolic blood pressure (1mmHg) 1.00 (0.99–1.00), 𝑃 = 0.67
CV comorbiditiesa (0 = no; 1 = yes) 1.55 (1.24–1.94), 𝑃 < 0.001
Antihypertensive treatment (0 = no; 1 = yes) 1.12 (0.90–1.39), 𝑃 = 0.98
Dialysis vintage (1 month) 1.00 (1.00-1.00), 𝑃 < 0.001
Cholesterol (1mg/dL) 1.00 (1.00-1.00), 𝑃 = 0.002
Hb (1 g/dL) 0.93 (0.86–0.99), 𝑃 = 0.04
Phosphate (1mg/dL) 1.01 (0.94–1.08), 𝑃 = 0.80
Albumin (1 g/dL) 0.70 (0.55–0.88), 𝑃 = 0.002
CRP (1mg/L) 1.00 (1.00-1.00), 𝑃 = 0.56
Body Mass Index (BMI) (1 kg/m2) 0.99 (0.97–1.02), 𝑃 = 0.46
GOT (1UI/L) 1.01 (0.99–1.03), 𝑃 = 0.45
GPT (1UI/L) 1.00 (0.99–1.01), 𝑃 = 0.98
Bilirubin (1mg/dL) 0.91 (0.54–1.51), 𝑃 = 0.70
HbsAg (0 = no; 1 = yes) 0.73 (0.37–1.44), 𝑃 = 0.37
HCV (0 = no; 1 = yes) 0.81 (0.56–1.16), 𝑃 = 0.25
Cirrhosis/hepatitis (0 = no; 1 = yes) 1.26 (0.71–2.24), 𝑃 = 0.44
Current alcohol consumption (0 = no; 1 = yes) 1.12 (0.88–1.42), 𝑃 = 0.34
Data are expressed as hazard ratio, 95% confidence interval (CI), and 𝑃 values.
aCV comorbidities were defined as in Table 1.
Circulating levels of Alk-Phos in ESKD in patients without
obvious liver diseasemainly reflect bone turnover [31]. In this
regard, it is worth mentioning that, in in vitro experiments in
vascular and bone cells, oxidative stress is a strong inducer
of alkaline phosphatase and a key event promoting the
transition of the vascular cells phenotype into calcifying
cells [15]. Alk-Phos is seen as a host defence molecule that
is part of the innate immune response to bacterial agents.
Indeed this enzyme is potently induced by IL-6, TNF-𝛼, and
bacterial lipopolysaccharide, all factors typically associated
with inflammation and high oxidative stress [32]. Thus the
hypothesis that oxidative stress may interact with Alk-Phos
in organ damage and ultimately in major clinical outcomes
is biologically well founded. However, in no study was such
an interaction formally investigated.The issue is of particular
relevance in ESKD because high levels of oxidative stress
are a hallmark in these patients [6, 7]. Various biomarkers
of oxidative stress are currently applied in clinical research
[33–36] and among these GGT is seen as the one that better
captures whole body oxidative stress [8]. Of note, in previous
studies in ESKD, GGT exhibited a much stronger link with
mortality [10] than other oxidative stress biomarkers tested
in the same population. With this background in mind we
set out to make a detailed analysis of the interaction between
GGT and alkaline phosphatase for risk of death, the most
solid outcome measure in clinical studies. Along with the
working hypothesis we found that GGT is a relevant modifier
of the risk of Alk-Phos for mortality. Indeed in a crude
analysis the interaction term indicated that a fixed increase
in Alk-Phos levels (50UI/L) produced a stepwise increase in
the risk of death across GGT quintile (HR = 1.08 per GGT
quintile). Importantly, this interaction was unmodified by
adjustment for a comprehensive series of risk factors formor-
tality, including CV comorbidities, clinical risk factors, BMI,
risk factors peculiar to ESKD like haemoglobin, C-reactive
protein, serum albumin and phosphate, and biomarkers of
liver disease and alcohol intake. The fact that the interaction
was independent of concomitant liver disease indicates that
the effect of modification of GGT on the Alk-Phos death
relationship does not represent a mere effect of liver damage
but a more general phenomenon, more likely oxidative stress
[8].
Our study has limitations. First, our observations are
limited to a single ESKD cohort of Caucasian patients.
Therefore, confirmation in a second ESKD cohort and in
studies in other ethnicities is still needed for establishing the
external generalizability of our findings. Second, even though
we did a comprehensive adjustment for a long list of potential
confounders, confounding for unmeasured and/or unknown
risk factors remains possible, an issue that can be solved only
6 Oxidative Medicine and Cellular Longevity
by a clinical trial. In this regard, it is worth mentioning that
drugs that reduce serumAlk-Phos are being investigated and
that one of these drugs has produced a significant reduction
in vascular calcification and bone loss in ESKD patients [37].
Our findings suggest that the protective effect of this drug
may be attenuated in patients with high GGT, hypothesis
which may be formally tested in secondary analyses of the
same trial.
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